Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 4/20 | 0.39 |
| ▸ | DRD2 | P14416 | 3/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.38 |
| ▸ | VCP | P55072 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24671522 | 0.94 | HSD11B1 (0.43) | HRH3KCNH2CYP2D6GNAI3GNAO1 | |
| SCHEMBL25075012 | 0.86 | HSD11B1 (0.42) | HRH3KCNH2CYP2D6GNAI3GNAO1 | |
| SCHEMBL24475418 | 0.85 | HRH3 (0.46) | HRH3KCNH2CYP2D6DRD3DRD2 | |
| SCHEMBL22520624 | 0.85 | CACNA2D1 (0.43) | HRH3KCNH2CYP2D6HSD11B1EPHX2 | |
| SCHEMBL22520728 | 0.84 | HRH3 (0.43) | HRH3KCNH2CYP2D6DRD3DRD2 | |
| SCHEMBL25075014 | 0.84 | GNAI3 (0.42) | GNAI3GNAO1GNAI1HSD11B1DRD3 | |
| SCHEMBL26263767 | 0.83 | HRH3 (0.50) | HRH3KCNH2CYP2D6GNAI3GNAO1 | |
| SCHEMBL26295687 | 0.82 | HRH3 (0.50) | HRH3KCNH2CYP2D6HSD11B1DRD3 | |
| SCHEMBL20046477 | 0.81 | VCP (0.44) | HRH3KCNH2CYP2D6DRD3DRD2 | |
| SCHEMBL24501935 | 0.80 | EPHX2 (0.43) | HRH3KCNH2CYP2D6GNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024064358-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| US-20220169643-A1 | ESTROGEN RECEPTOR DEGRADING PROTACS | ASTRAZENECA UK LIMITED (GB) | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169643-A1 | ESTROGEN RECEPTOR DEGRADING PROTACS | ESR1, GPER1, ESRRG | HRH3 1546/4885KCNH2 3717/4885CYP2D6 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.